Skip to main content
. Author manuscript; available in PMC: 2024 Aug 21.
Published in final edited form as: Sci Transl Med. 2024 Jul 3;16(754):eadk3295. doi: 10.1126/scitranslmed.adk3295

Table 1.

Participant Demographics, Clinical Factors, and Long COVID History

Pt # Variant Wave at Time of Infection Hosp. During Acute Infection Days from Infection to PET Scan Days From Vaccine to PETa Sex Age b LC Symptom Countc Presence of LC Symptom Phenotype at Time of Imaging Anti-N Ab at PETd Days from Infection to Gut Biopsye % Gut Cells with Spike RNA (ss, ds)
Fatigue Pulm Cardiac URI GI Neuro
1 Pre-Omicron N 27 135 F 26 2 Y Y N N N N Y -
2 Pre-Omicron N 29 113 M 37 1 N Y N N N N Y -
3 Pre-Omicron N 42 151 M 30 4 N Y Y N N N Y -
4 Pre-Omicron N 44 149 M 64 0 N N N N N N Y -
5 Pre-Omicron N 48 199 M 29 5 Y N Y N Y Y Y -
6 Pre-Omicron N 50 N/Af F 32 4 Y Y N N N Y N -
7 Omicron N 64 6 M 42 14 Y Y N N Y Y N -
8 Omicron N 65 386 F 64 0 N N N N N N N -
9 Omicron N 83 183 F 59 0 N N N N N N Y -
10 Omicron N 95 246 M 47 0 N N N N N N Y 158 2.56, 0.09
11 Omicron N 114 286 F 30 8 Y N Y Y Y N Y -
12 Pre-Omicron N 193 137 F 28 13 Y Y N N Y Y N -
13 Omicron N 205 122 F 47 6 Y Y N N N Y N -
14 Omicron N 231 63 M 35 4 Y N Y N Y Y Y -
15 Omicron N 246 302 M 65 6 Y N N Y Y Y N 213 1.57, 0
16 Pre-Omicron Yg 260 118 M 54 8 Y Y N Y N Y N 442 1.83, 0.7
17 Pre-Omicron h N 406 219 F 33 0 N N N N N N Y -
18 Pre-Omicron N 617 320 F 32 7 Y N Y N N Y N 645 0.38, 0
19 Pre-Omicron N 625 122 M 46 14 Y Y N N Y Y Y -
20 Pre-Omicron N 641 321 M 28 11 Y N Y N Y Y Y -
21 Pre-Omicron N 654 425 F 33 15 Y Y Y N Y Y N -
22 Pre-Omicron N 663 248 M 52 6 Y Y N Y Y Y Y 676 1.55,1.22
23 Pre-Omicron N 890 211 M 52 0 N N N N N N Y -
24 Pre-Omicron Yi 910 155 F 59 6 Y Y N N Y Y N -

Pt, participant; Hosp., hospitalized; Pulm, pulmonary; URI, upper respiratory; GI, gastrointestinal; Neuro, neurocognitive; LC, Long COVID; Y, Yes, N, No; F, female; M, male; ss, single-stranded SARS-CoV-2 Spike RNA, ds, double-stranded SARS-CoV-2 Spike RNA

a

Days from last COVID-19 vaccine dose to PET imaging

b

Age in years

c

Number of participant reported symptoms at the time of PET imaging (out of 32 total)

d

Anti-Nucleocapsid antibody detected at time of PET

e

Days from COVID-19 infection to biopsy; all participants had a least one Long COVID symptoms at the time of sigmoidoscopy and rectosigmoid tissue collection

f

Participant was not vaccinated prior to PET imaging

g

Participant did not require intensive care but received supplemental oxygen during hospitalization

h

Participant initially infected during pre-Omicron wave but had two documented re-infections. Days from infection to PET scan calculated from last Omicron reinfection

i

Participant did not require intensive care or supplemental oxygen during hospitalization